TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17401488

Group type: EXPERIMENTAL
Intervention: Immunosuppression with tacrolimus, azathioprine and prednisone (GI, N = 38)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 2 doses of daclizumab, mycophenolate mofetil (MMF), and prednisone (GII, N = 33)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 2 doses of daclizumab, MMF, sirolimus and prednisone (GIII, N = 21)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Patients of black ethnicity
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall incidence of post-transplant diabetes mellitus
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall incidence of cytomegalovirus disease
Number of subjects: 92
Study: 14653099

Group type: EXPERIMENTAL
Intervention: Physiotherapy with drugs
Number of subjects: 96

Group type: COMPARATOR
Intervention: Drugs (control group)
Number of subjects: 96
Study: 10834687

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg at 8-hr intervals through nasogastric tube)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo (administered at 8-hr intervals through nasogastric tube)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 8863918

Group type: EXPERIMENTAL
Intervention: Homosexual AIDS patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Leukaemia patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All variables
Number of subjects: 102
Study: 1736128

Group type: EXPERIMENTAL
Intervention: Hydrotherapy in a thermomineral institution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hydrotherapy in a hospital exercise-bath (control group)
Number of subjects: 46
Study: 6743506

Group type: EXPERIMENTAL
Intervention: Screening (clinical examination every year and mammography on alternate years)
Number of subjects: 65000

Group type: COMPARATOR
Intervention: Control (non-screening group)
Number of subjects: 65000
Study: 2876326

Group type: EXPERIMENTAL
Intervention: Homoeopathic preparation of mixed grass pollens
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 29311020

Group type: EXPERIMENTAL
Intervention: Incision and drainage along with oral antibiotics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incision and drainage only
Number of subjects: 40
Study: 27571256

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (continuous infusion at a rate of 0.1 μg kg h; n = 38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 38)
Number of subjects: 76
Study: 24943245

Group type: EXPERIMENTAL
Intervention: RMN-guided single-ring ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: RMN-guided circumferential PVA
Number of subjects: 80
Study: 22228112

Group type: COMPARATOR
Intervention: P0 (0 seconds interrepetition rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: P20 (20 seconds interrepetition rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: P40 (40 seconds interrepetition rest)
Number of subjects: 10
Study: 20719923

Group type: EXPERIMENTAL
Intervention: BOLD responses to objects presented in the upper visual field (UVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOLD responses to scrambled objects presented in the upper visual field (UVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOLD responses to objects presented in the lower visual field (LVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOLD responses to scrambled objects presented in the lower visual field (LVF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of BOLD responses to objects versus scrambled objects in both UVF and LVF
Number of subjects: 0
Study: 18565744

Group type: EXPERIMENTAL
Intervention: 64 Gy in 32 fractions over 6.5 weeks
Number of subjects: 843

Group type: COMPARATOR
Intervention: 74 Gy in 37 fractions over 7.5 weeks
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Use of electronic portal imaging (EPI)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Use of low melting point alloy (LMPA) blocks
Number of subjects: 843
Study: 16168871

Group type: EXPERIMENTAL
Intervention: Senior Walking Environmental Assessment Tool (SWEAT)
Number of subjects: 355
Study: 12795572

Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducational therapy (n = 28)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Individual treatment (n = 25)
Number of subjects: 53
Study: 10819853

Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 1862
Study: 8793675

Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (37 degrees C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold blood cardioplegia (4 degrees C)
Number of subjects: 40
Study: 1352930

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 4 weeks, then 40 mg daily for another 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6498044

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: bupivacaine groups (0.5% and 0.75%)
Number of subjects: 100
Study: 30499599

Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelet concentrates (Mirasol)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Untreated platelet concentrates
Number of subjects: 448
Study: 30113651

Group type: EXPERIMENTAL
Intervention: Dapagliflozin at 10 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Empagliflozin at 10 mg
Number of subjects: 46
Study: 27208669

Group type: EXPERIMENTAL
Intervention: Counselling intervention delivered by family doctors
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Favourable doctor communication
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Awareness of the abuse and readiness for help
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Weave as an avenue to help
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Doctor's communication
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Role in providing care for IPV
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Emotional health
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Doctors' time
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Managing the disclosure process
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Viewing primary care as a safe option
Number of subjects: 137
Study: 25332247

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control: Placebo plus trastuzumab plus docetaxel
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: High HER2 protein, high HER2 and HER3 mRNA levels, wild-type PIK3CA, low sHER2
Number of subjects: 808
Study: 22190020

Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet (mean GL/d = 125)
Number of subjects: 80

Group type: COMPARATOR
Intervention: High-glycemic load diet (mean GL/d = 250)
Number of subjects: 80
Study: 20506154

Group type: EXPERIMENTAL
Intervention: Proximal embolic protection (PEP) during angioplasty
Number of subjects: 31

Group type: COMPARATOR
Intervention: No proximal embolic protection (without PEP) during angioplasty
Number of subjects: 31
Study: 18227304

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea (IH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study: 16450596

Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg IV)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Isotonic saline (1 liter)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional maintenance fluids (Control)
Number of subjects: 37
Study: 12826169

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d (po) plus vitamin D (800 UI cholecalciferol) and calcium (2.5 g of CaCO3)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (vitamin D plus calcium at the same dose)
Number of subjects: 14
Study: 10760045

Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN‐α)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 144
Study: 8799780

Group type: EXPERIMENTAL
Intervention: Single 1 g oral dose of azithromycin (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard duration therapy (Group S)
Number of subjects: 200
Study: 1386071

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.1 mg/kg) plus ipratropium bromide (50 micrograms)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fenoterol (0.1 mg/kg) and placebo
Number of subjects: 61
Study: 6364761

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Surgical therapy (CABG)
Number of subjects: 194
Study: 30821649

Group type: EXPERIMENTAL
Intervention: Telephone-based Cognitive Behavioral Therapy (CBT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 11
Study: 29730798

Group type: EXPERIMENTAL
Intervention: Infratrochlear nerve block (ITB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard treatment without a nerve block)
Number of subjects: 60
Study: 27543364

Group type: EXPERIMENTAL
Intervention: Melatonin cream 12.5%
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Melatonin cream 0.5%
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Melatonin cream 2.5%
Number of subjects: 23
Study: 24629911

Group type: EXPERIMENTAL
Intervention: Dietary olestra (15 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vegetable oil (VO)
Number of subjects: 28
Study: 22409921

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Granule
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20941469

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin plus ezetimibe
Number of subjects: 0
Study: 18525297

Group type: EXPERIMENTAL
Intervention: Radiation therapy with concurrent daily platinum chemotherapy (77 Gy, 1.1 Gy bid)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Radiation therapy without concurrent chemotherapy (70 Gy, 1.8‐2.0 Gy per fraction)
Number of subjects: 289
Study: 16005555

Group type: EXPERIMENTAL
Intervention: Sidestepping trials with neuromuscular control training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sidestepping trials
Number of subjects: 20
Study: 12447516

Group type: EXPERIMENTAL
Intervention: Cisatracurium-induced curarization with no response at orbicularis oculi to TOF stimulation (group 1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cisatracurium-induced curarization with two responses at orbicularis oculi to TOF stimulation (group 2)
Number of subjects: 102
Study: 10071177

Group type: EXPERIMENTAL
Intervention: 15 mg of d‐Fenfluramine (d‐Fen)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg of Ipsapirone (Ips)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8868007

Group type: EXPERIMENTAL
Intervention: Roxatidine 150 mg
Number of subjects: 215

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 215
Study: 2347956

Group type: COMPARATOR
Intervention: Ceftriaxone 0.5 g IV without probenecid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 0.5 g IV with probenecid (0.5 g at 10 and 2 hours prior to ceftriaxone and 0.5 g q12h X 3 doses post ceftriaxone)
Number of subjects: 6
Study: 23135

Group type: EXPERIMENTAL
Intervention: Clazepam (30 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Chlordiazepoxide (30 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31404033

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment using the Valeda Light Delivery System, 3 times per week for 3-4 weeks over 1 year.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 30723886

Group type: EXPERIMENTAL
Intervention: Sevoflurane, increasing concentrations technique (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane, vital capacity technique (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous propofol (Group C)
Number of subjects: 60
Study: 27741377

Group type: EXPERIMENTAL
Intervention: Alpha cradle (AC) immobilisation system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vacuum bag (VB) immobilisation system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head rest and base plate (HB) immobilisation system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26147563

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 63
Study: 24274210

Group type: EXPERIMENTAL
Intervention: Lidocaine-soaked biodegradable synthetic polyurethane foam
Number of subjects: 63

Group type: COMPARATOR
Intervention: Saline-soaked polyurethane foam
Number of subjects: 63
Study: 22108353

Group type: EXPERIMENTAL
Intervention: Aphakic contact lenses (CL)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intraocular lenses (IOL)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Overall (both CL and IOL)
Number of subjects: 83
Study: 18413006

Group type: EXPERIMENTAL
Intervention: Structured triglycerides (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: MCT/LCT emulsion (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: LCT emulsion (Group C)
Number of subjects: 45
Study: 15975964

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months
Number of subjects: 49
Study: 12874091

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) administered in the morning
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) administered at bedtime
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valsartan administered at bedtime
Number of subjects: 90

Group type: COMPARATOR
Intervention: Valsartan administered in the morning vs bedtime
Number of subjects: 90
Study: 10859151

Group type: EXPERIMENTAL
Intervention: Oral tablet dosing of rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral solution dosing of rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous dosing of rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral and intravenous dosing of rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All formulations of rosiglitazone
Number of subjects: 0
Study: 9695144

Group type: EXPERIMENTAL
Intervention: Diskhaler
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Easi‐Breathe
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diskus
Number of subjects: 10
Study: 8026109

Group type: EXPERIMENTAL
Intervention: Fish-oil product with a high percentage of omega-3-polyunsaturated fatty acids (K 85, 6g daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Corn oil (6g daily)
Number of subjects: 32
Study: 2483237

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose heparin (12,500 i.u. daily by subcutaneous route)
Number of subjects: 0
Study: 790128

Group type: EXPERIMENTAL
Intervention: 100mg raubasine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31109172

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27987252

Group type: EXPERIMENTAL
Intervention: SAR342434 solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: US-approved Humalog
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EU-approved Humalog
Number of subjects: 30
Study: 25803777

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 50 mg in 10 cc, self-administered 3 times daily at meal times
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (identically appearing)
Number of subjects: 72
Study: 24339684

Group type: EXPERIMENTAL
Intervention: ECCE with PCIOL implantation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Phacoemulsification with PCIOL implantation
Number of subjects: 115
Study: 21183763

Group type: COMPARATOR
Intervention: Conventional strategy (325 mg aspirin orally and a loading dose of 600 mg clopidogrel)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aggressive strategy (same aspirin and clopidogrel as conventional, plus intravenous glycoprotein IIb/IIIa inhibitor)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Number of subjects: 36
Study: 19235600

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 20
Study: 17726250

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 U/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 IU/day, two times a day
Number of subjects: 150

Group type: COMPARATOR
Intervention: No prophylaxis (Control group)
Number of subjects: 150
Study: 15102080

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐galactosidase A (r‐halphaGalA), administered i.v. at 1 mg per kg every 2 weeks for 5 months (Phase 3 trial)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐galactosidase A (r‐halphaGalA) continued in open label extension study
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐galactosidase A (r‐halphaGalA)
Number of subjects: 58
Study: 11563996

Group type: EXPERIMENTAL
Intervention: Nizatidine, 75 mg
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study: 9351881

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 1562407

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled polyclonal human immunoglobulin (IgG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 111In granulocytes
Number of subjects: 14
Study: 2858749

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation by nasogastric intubation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nightly oral formula supplements
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Zinc, iron, folate, and vitamin E supplements
Number of subjects: 5
Study: 30569776

Group type: EXPERIMENTAL
Intervention: Conservative pacing strategy in classic style
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vmax and %Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vmax to finish sprint
Number of subjects: 12
Study: 29595685

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 27031055

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 202

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 202
Study: 25341145

Group type: EXPERIMENTAL
Intervention: Normal saline with 0.9% benzyl alcohol (test group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Preservative-free normal saline (control group)
Number of subjects: 138
Study: 22592929

Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol vaginally 12 hours before hysteroscopy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no cervical priming)
Number of subjects: 55
Study: 20098847

Group type: EXPERIMENTAL
Intervention: Blue Light treatment (8 times, twice a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical Benzoyl Peroxide 5% formulation (auto-applied twice a day, every day)
Number of subjects: 60
Study: 17006433

Group type: COMPARATOR
Intervention: 5 mg THC
Number of subjects: 15
Study: 15837967

Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiation therapy (HART), 57.6 Gy (1.5 Gy tid for 2.5 weeks)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Once-daily radiation therapy (qdRT), 64 Gy (2 Gy/d)
Number of subjects: 141
Study: 11880910

Group type: EXPERIMENTAL
Intervention: Continuous outcome variables
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dichotomous outcome variables
Number of subjects: 76
Study: 9817169

Group type: EXPERIMENTAL
Intervention: CVD‐IP
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 7716598

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: four-gas mixture (oxygen 21.0%, argon 48.6%, nitrogen 19.3%, helium 11.1%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: air
Number of subjects: 18
Study: 2189950

Group type: EXPERIMENTAL
Intervention: Adriamycin, cyclophosphamide, and tamoxifen (ACT)
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Adriamycin, fluorouracil, and tamoxifen (PAFT)
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Melphalan, fluorouracil, and tamoxifen (PFT)
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Tamoxifen alone (TAM)
Number of subjects: 1124
Study: 116278

Group type: EXPERIMENTAL
Intervention: Piracetam (UCB 6215, Nootropyl)
Number of subjects: 0
Study: 31549577

Group type: EXPERIMENTAL
Intervention: Spironolactone, 50 mg orally once daily for 12 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Eplerenone, 50 mg orally once daily for 12 months
Number of subjects: 52
Study: 28686777

Group type: EXPERIMENTAL
Intervention: Topical dapsone gel, 7.5%
Number of subjects: 4340

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 4340